Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL)

Kena C. Miller,Myron S. Czuczman,Laurie DiMiceli,Swaminathan Padmanabhan,David S. Lawrence,Zale P. Bernstein,Kenichi Takeshita,David Spaner,Catriona Byrne,C Crystal,Asher Chanan-Khan

Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL)

2016

Kena C. Miller
Myron S. Czuczman
Laurie DiMiceli
Swaminathan Padmanabhan
David S. Lawrence
Zale P. Bernstein
Kenichi Takeshita
David Spaner
Catriona Byrne
C Crystal
Asher Chanan-Khan

6517 Background: Tumor microenvironment (ME) is critical in CLL pathogenesis. Targeting the ME is a novel approach in CLL therapeutics. Lenalidomide (Revlimid, L) is an immunomodulating agent (IMiD...

Keywords:

Pathology
Chronic lymphocytic leukemia
Immunomodulating Agent
Lenalidomide
Refractory
Cancer research
Tumor microenvironment
Pathogenesis
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations